TET2 and acute myeloid leukemia: The mutational landscape is variable, with frequencies of FMS-like tyrosine kinase 3 (FLT3), nucleophosmin 1 (NPM1), neuroblastoma RAS viral oncogene homologue (NRAS), isocitrate dehydrogenase 2 (IDH2), DNA methyltransferase 3a (DNMT3A), and ten-eleven translocation 2 (TET2) mutations similar to those observed in AML de novo [14,15,16].